Literature DB >> 26747893

Anticancer Teamwork: Cross-Presenting Dendritic Cells Collaborate with Therapeutic Monoclonal Antibodies.

Céline Robert-Tissot1, Daniel E Speiser2.   

Abstract

Cross-presentation of tumor antigens represents a key pathway in antitumor immune responses that can be exploited to synergize not only with the already prominent "checkpoint blockade," but also with newer attempts to use T-cell stimulatory monoclonal antibodies in immunotherapy. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26747893     DOI： 10.1158/2159-8290.CD-15-1366

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

1.  PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.

Authors:  Carmen Stecher; Claire Battin; Judith Leitner; Markus Zettl; Katharina Grabmeier-Pfistershammer; Christoph Höller; Gerhard J Zlabinger; Peter Steinberger
Journal:  Front Immunol       Date:  2017-05-22       Impact factor: 7.561

2.  Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery.

Authors:  Wenyan Hao; Yuexin Cui; Yueyue Fan; Mengyu Chen; Guobao Yang; Yuli Wang; Meiyan Yang; Zhiping Li; Wei Gong; Yang Yang; Chunsheng Gao
Journal:  J Nanobiotechnology       Date:  2021-11-20       Impact factor: 10.435

3.  Virus-Mimic mRNA Vaccine for Cancer Treatment.

Authors:  Chaoyang Meng; Zhe Chen; Junhua Mai; Qing Shi; Shaohui Tian; Louis Hinkle; Jun Li; Zhe Zhang; Maricela Ramirez; Licheng Zhang; Yitian Xu; Jilu Zhang; Ping-Ying Pan; Shu-Hsia Chen; Hangwen Li; Haifa Shen
Journal:  Adv Ther (Weinh)       Date:  2021-09-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.